Latest News by Industry
LEXINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancers and infectious disease, today provided a corporate update and reported financial results for the third quarter of 2022.
“Botensilimab has demonstrated impressive clinical responses in nine cold, treatment-resistant tumor types with strong durability, and we look forward to presenting expanded data in colorectal, ovarian, lung and sarcoma cohorts at a plenary session at SITC followed by our R&D event this Saturday,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “In light of these compelling clinical data, we have expanded our leadership team to accelerate the development and seek registration of botensilimab with the aim of delivering this potentially transformative new therapy to patients across multiple tumor types.”
Clinical update on botensilimab, Agenus’ innate and adaptive immune stimulator, to be presented in a plenary session of the SITC Annual Meeting
Initiated Phase 2 ACTIVATE trials in advanced MSS colorectal cancer and melanoma
Expanded clinical and regulatory leadership team to accelerate botensilimab development
Continued to advance clinical pipeline through company-led studies and corporate partnerships
Third Quarter 2022 Financial Results
We ended our third quarter 2022 with a cash, cash equivalent, and short-term investment balance of $218.2 million as compared to $238.3 million and $306.9 million on June 30, 2022, and December 31, 2021, respectively. Cash used in operations was $32.2 million for the quarter ended September 30, 2022, and $128 million for the nine-months then ended.
We recognized revenue of $22.8 million and incurred a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022. For the nine-months ended September 30, 2022, we recognized revenue of $69.6 million and incurred a net loss of $156.6 million, or $0.54 per share.
Non-cash operating expenses for the third quarter and nine-months ended September 30, 2022, were $22.2 million and $62.8 million respectively.
| Select Financial Information | ||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| September 30, 2022 | December 31, 2021 | |||||||||||||||
| Cash, cash equivalents and short-term investments | $ | 218,230 | $ | 306,923 | ||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues, royalty sales milestone | $ | 7,934 | $ | - | $ | 25,250 | $ | - | ||||||||
| Revenues, non-cash royalty | 9,224 | 12,593 | 27,001 | 28,903 | ||||||||||||
| Revenues, research and development | 4,573 | 238,986 | 13,220 | 242,265 | ||||||||||||
| Revenues, other | 1,041 | 1,375 | 4,167 | 4,236 | ||||||||||||
| Total Revenue | 22,772 | 252,954 | 69,638 | 275,404 | ||||||||||||
| Research and development expenses | 46,011 | 42,937 | 133,412 | 125,122 | ||||||||||||
| General and administrative expenses | 18,105 | 21,385 | 55,971 | 54,388 | ||||||||||||
| Cost of service revenue | 308 | 817 | 2,875 | 2,589 | ||||||||||||
| Other income | (971 | ) | (6,035 | ) | (9,745 | ) | (7,404 | ) | ||||||||
| Non-cash interest expense | 16,041 | 16,298 | 44,629 | 48,295 | ||||||||||||
| Non-cash contingent consideration fair value adjustment | (7 | ) | 275 | (950 | ) | 13,531 | ||||||||||
| Net (loss) income | $ | (56,715 | ) | $ | 177,277 | $ | (156,554 | ) | $ | 38,883 | ||||||
| Net (loss) income per share attributable to Agenus Inc. common stockholders, basic | $ | (0.19 | ) | $ | 0.76 | $ | (0.54 | ) | $ | 0.19 | ||||||
| Net (loss) income per share attributable to Agenus Inc. common stockholders, diluted | $ | (0.19 | ) | $ | 0.72 | $ | (0.54 | ) | $ | 0.18 | ||||||
| Cash (used in) provided by operations | $ | (32,191 | ) | $ | 131,373 | $ | (128,035 | ) | $ | 33,072 | ||||||
| Non-cash operating expenses | $ | 22,194 | $ | 23,127 | $ | 62,814 | $ | 81,421 | ||||||||
Conference Call
Tuesday, November 8, 2022, 8:30am ET
Dial-in numbers: (646) 307-1963 (US-NY) or (800) 715-9871 (US & CA)
Event ID: 6199615
Webcast
A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/2truok3j.
“The Road Taken” R&D Event
Agenus will host an in-person and virtual R&D event (“The Road Taken”) on Saturday, November 12th from 2:00 p.m. to 5:00 p.m. ET at the Prudential Tower in Boston, MA. The event will feature insights from leading cancer immunologists who will share their collective and individual expertise on the current and future state of cancer immunotherapy, including a deep dive into the botensilimab data presented at SITC. Institutional investors, research analysts, and key opinion leaders are invited to attend the event in-person and can RSVP by emailing investorrelations@agenusbio.com. To register for the live webcast, please click here.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety and tolerability profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact
Agenus Inc.
Nico Frelick
Investor Relations
781-674-4616
nico.frelick@agenusbio.com